-
Featured
Innovations in ALS Clinical Trials
Merit Cudkowicz, MD, MSc, chief of Neurology at Massachusetts General Hospital, discusses innovations in ALS clinical trials since she started in the field in 1994.
-
Featured
Advancements in the Treatment of Neurodegenerative Disease
In this video, Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory and the MassGeneral Institute of Neurodegenerative Disease, discusses her genetic research, specifically concerning neurodegenerative diseases like ALS and X-linked dystonia parkinsonism.
-
Featured
Identifying New Potential Therapeutic Targets for ALS FTD
Transcripts of repeat expansions in the C90RF72 gene undergo a repeat-associated non-AUG (RAN) translation pathway that generates multiple aberrant proteins. Researchers at Mass General Hospital identified new potential therapeutic targets for ALS FTD.
-
Lifetime Achievement Award Recognizes Catalyst of ALS Therapy Research and Development
The American Academy of Neurology recognizes the career achievements and global impact of Merit Cudkowicz, MD, MSc, for advancing ALS research and treatment.
-
Innovative Platform Trial Reshapes the Future of ALS Drug Discovery and Evaluation
Researchers at Massachusetts General Hospital and collaborators publish results of the first four drug candidates evaluated using the HEALEY ALS Platform Trial.
-
Antisense Drugs Mimic TDP-43 Function, Might Treat ALS and Some Dementias
Clotilde Lagier-Tourenne, MD, PhD, and colleagues have demonstrated in vitro and in vivo efficacy of antisense oligonucleotides in preventing missplicing of stathmin-2 in a mouse model of amyotrophic lateral sclerosis attributable to deficiency of the protein TDP-43.
ALS Contributors
-
Clotilde Lagier-Tourenne, MD, PhD
Associate Professor of Neurology, Massachusetts General Hospital and Harvard Medical School
Recent Article
Antisense Drugs Mimic TDP-43 Function, Might Treat ALS and Some Dementias -
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Novel Target Identified for Treatment of ALS -
James D. Berry, MD, MPH
Co-director, Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic
Recent Article
Healey Platform ALS Trial Expected to Expedite U.S. Approval of New Treatments -
Merit Ester Cudkowicz, MD, MSc
Chief, Neurology Service, Director of the Sean M. Healey & AMG Center for ALS at Mass General, Director of Neurological Clinical Research Institute and the Jilieane Dorn Professor of Neurology, Harvard Medical School
Recent Article
Lifetime Achievement Award Recognizes Catalyst of ALS Therapy Research and Development -
Nazem Atassi, MD
Associate Director, Neurological Clinical Research Institute (NCRI), Mass General Hospital, Associate Professor of Neurology, Harvard Medical School
Recent Article
High-Dose Tamoxifen "Wins" Selection Trial in ALS